2093 related articles for article (PubMed ID: 24007748)
41. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study.
Dimopoulos M; Quach H; Mateos MV; Landgren O; Leleu X; Siegel D; Weisel K; Yang H; Klippel Z; Zahlten-Kumeli A; Usmani SZ
Lancet; 2020 Jul; 396(10245):186-197. PubMed ID: 32682484
[TBL] [Abstract][Full Text] [Related]
42. Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma.
Dimopoulos MA; Palumbo A; Corradini P; Cavo M; Delforge M; Di Raimondo F; Weisel KC; Oriol A; Hansson M; Vacca A; Blanchard MJ; Goldschmidt H; Doyen C; Kaiser M; Petrini M; Anttila P; Cafro AM; Raymakers R; San-Miguel J; de Arriba F; Knop S; Röllig C; Ocio EM; Morgan G; Miller N; Simcock M; Peluso T; Herring J; Sternas L; Zaki MH; Moreau P
Blood; 2016 Jul; 128(4):497-503. PubMed ID: 27226434
[TBL] [Abstract][Full Text] [Related]
43. Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low - dose dexamethasone versus high - dose dexamethasone in refractory or relapsed and refractory multiple myeloma.
Weisel KC; Dimopoulos MA; Moreau P; Lacy MQ; Song KW; Delforge M; Karlin L; Goldschmidt H; Banos A; Oriol A; Alegre A; Chen C; Cavo M; Garderet L; Ivanova V; Martinez-Lopez J; Knop S; Yu X; Hong K; Sternas L; Jacques C; Zaki MH; San Miguel J
Haematologica; 2016 Jul; 101(7):872-8. PubMed ID: 27081177
[TBL] [Abstract][Full Text] [Related]
44. [Pomalidomide in the treatment of relapsed and refractory multiple myeloma].
Roziaková L; Mistrík M; Bátorová A
Klin Onkol; 2014; 27(5):318-25. PubMed ID: 25312708
[TBL] [Abstract][Full Text] [Related]
45. Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma.
Mark TM; Forsberg PA; Rossi AC; Pearse RN; Pekle KA; Perry A; Boyer A; Tegnestam L; Jayabalan D; Coleman M; Niesvizky R
Blood Adv; 2019 Feb; 3(4):603-611. PubMed ID: 30792190
[TBL] [Abstract][Full Text] [Related]
46. Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial.
Trněný M; Lamy T; Walewski J; Belada D; Mayer J; Radford J; Jurczak W; Morschhauser F; Alexeeva J; Rule S; Afanasyev B; Kaplanov K; Thyss A; Kuzmin A; Voloshin S; Kuliczkowski K; Giza A; Milpied N; Stelitano C; Marks R; Trümper L; Biyukov T; Patturajan M; Bravo MC; Arcaini L;
Lancet Oncol; 2016 Mar; 17(3):319-331. PubMed ID: 26899778
[TBL] [Abstract][Full Text] [Related]
47. A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma.
Mikhael J; Richardson P; Usmani SZ; Raje N; Bensinger W; Karanes C; Campana F; Kanagavel D; Dubin F; Liu Q; Semiond D; Anderson K
Blood; 2019 Jul; 134(2):123-133. PubMed ID: 30862646
[TBL] [Abstract][Full Text] [Related]
48. Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial.
San-Miguel JF; Hungria VT; Yoon SS; Beksac M; Dimopoulos MA; Elghandour A; Jedrzejczak WW; Günther A; Nakorn TN; Siritanaratkul N; Schlossman RL; Hou J; Moreau P; Lonial S; Lee JH; Einsele H; Sopala M; Bengoudifa BR; Binlich F; Richardson PG
Lancet Haematol; 2016 Nov; 3(11):e506-e515. PubMed ID: 27751707
[TBL] [Abstract][Full Text] [Related]
49. A multicenter, open-label, phase 2 study of lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: the MM-021 trial.
Hou J; Du X; Jin J; Cai Z; Chen F; Zhou DB; Yu L; Ke X; Li X; Wu D; Meng F; Ai H; Zhang J; Wortman-Vayn H; Chen N; Mei J; Wang J
J Hematol Oncol; 2013 Jun; 6():41. PubMed ID: 23782711
[TBL] [Abstract][Full Text] [Related]
50. Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial.
Zelenetz AD; Barrientos JC; Brown JR; Coiffier B; Delgado J; Egyed M; Ghia P; Illés Á; Jurczak W; Marlton P; Montillo M; Morschhauser F; Pristupa AS; Robak T; Sharman JP; Simpson D; Smolej L; Tausch E; Adewoye AH; Dreiling LK; Kim Y; Stilgenbauer S; Hillmen P
Lancet Oncol; 2017 Mar; 18(3):297-311. PubMed ID: 28139405
[TBL] [Abstract][Full Text] [Related]
51. Pomalidomide: A Review in Relapsed and Refractory Multiple Myeloma.
Hoy SM
Drugs; 2017 Nov; 77(17):1897-1908. PubMed ID: 29110190
[TBL] [Abstract][Full Text] [Related]
52. Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom).
Knop S; Gerecke C; Liebisch P; Topp MS; Platzbecker U; Sezer O; Vollmuth C; Falk K; Glasmacher A; Maeder U; Einsele H; Bargou RC
Blood; 2009 Apr; 113(18):4137-43. PubMed ID: 19182205
[TBL] [Abstract][Full Text] [Related]
53. Pomalidomide-bortezomib-dexamethasone in relapsed or refractory multiple myeloma: Japanese subset analysis of OPTIMISMM.
Sunami K; Matsue K; Suzuki K; Takezako N; Shinagawa A; Sakurai S; Tamakoshi H; Biyukov T; Peluso T; Richardson P
Cancer Sci; 2020 Jun; 111(6):2116-2122. PubMed ID: 32297407
[TBL] [Abstract][Full Text] [Related]
54. Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study.
Kumar SK; Berdeja JG; Niesvizky R; Lonial S; Laubach JP; Hamadani M; Stewart AK; Hari P; Roy V; Vescio R; Kaufman JL; Berg D; Liao E; Di Bacco A; Estevam J; Gupta N; Hui AM; Rajkumar V; Richardson PG
Lancet Oncol; 2014 Dec; 15(13):1503-1512. PubMed ID: 25456369
[TBL] [Abstract][Full Text] [Related]
55. Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial.
Jackson GH; Davies FE; Pawlyn C; Cairns DA; Striha A; Collett C; Waterhouse A; Jones JR; Kishore B; Garg M; Williams CD; Karunanithi K; Lindsay J; Wilson JN; Jenner MW; Cook G; Kaiser MF; Drayson MT; Owen RG; Russell NH; Gregory WM; Morgan GJ;
Lancet Haematol; 2019 Dec; 6(12):e616-e629. PubMed ID: 31624047
[TBL] [Abstract][Full Text] [Related]
56. Pomalidomide: a review of its use in patients with recurrent multiple myeloma.
Scott LJ
Drugs; 2014 Apr; 74(5):549-62. PubMed ID: 24590685
[TBL] [Abstract][Full Text] [Related]
57. Efficacy and safety of generic pomalidomide plus low-dose dexamethasone in relapsed or refractory multiple myeloma: a multicenter, open-label, single-arm trial.
Zhou H; Wang Y; Chen J; He A; Jin J; Lu Q; Zhao Y; Li J; Hou M; Su L; Lai X; Wang W; Liu L; Ma Y; Gao D; Lai W; Zhou X; Jing H; Zhang J; Yang W; Ran X; Lin C; Hao J; Xiao T; Huang Z; Zhu Z; Wang Q; Fang B; Wang B; Song Y; Cai Z; Liu B; Zhu Y; Yang X; Kang X; Li J; Chen W
Ann Hematol; 2024 Mar; 103(3):855-868. PubMed ID: 38112795
[TBL] [Abstract][Full Text] [Related]
58. Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma.
Lacy MQ; Hayman SR; Gertz MA; Dispenzieri A; Buadi F; Kumar S; Greipp PR; Lust JA; Russell SJ; Dingli D; Kyle RA; Fonseca R; Bergsagel PL; Roy V; Mikhael JR; Stewart AK; Laumann K; Allred JB; Mandrekar SJ; Rajkumar SV
J Clin Oncol; 2009 Oct; 27(30):5008-14. PubMed ID: 19720894
[TBL] [Abstract][Full Text] [Related]
59. Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial results.
Leleu X; Karlin L; Macro M; Hulin C; Garderet L; Roussel M; Arnulf B; Pegourie B; Kolb B; Stoppa AM; Brechiniac S; Marit G; Thielemans B; Onraed B; Mathiot C; Banos A; Lacotte L; Tiab M; Dib M; Fuzibet JG; Petillon MO; Rodon P; Wetterwald M; Royer B; Legros L; Benboubker L; Decaux O; Escoffre-Barbe M; Caillot D; Fermand JP; Moreau P; Attal M; Avet-Loiseau H; Facon T;
Blood; 2015 Feb; 125(9):1411-7. PubMed ID: 25575538
[TBL] [Abstract][Full Text] [Related]
60. Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial.
Dimopoulos MA; Richardson PG; Bahlis NJ; Grosicki S; Cavo M; Beksaç M; Legieć W; Liberati AM; Goldschmidt H; Belch A; Magen H; Larocca A; Laubach JP; Petrucci MT; Reece D; White D; Mateos MV; Špička I; Lazaroiu M; Berdeja J; Kaufman JL; Jou YM; Ganetsky A; Popa McKiver M; Lonial S; Weisel K;
Lancet Haematol; 2022 Jun; 9(6):e403-e414. PubMed ID: 35550060
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
